Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
14 hedge funds and large institutions have $3.26M invested in Plus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
61% more capital invested
Capital invested by funds: $2.03M → $3.26M (+$1.23M)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
7% less funds holding
Funds holding: 15 → 14 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 3 |
Morgan Stanley
New York
|
+$120K |
| 4 |
OCA
Otter Creek Advisors
Palm Beach Gardens,
Florida
|
+$85.2K |
| 5 |
BlackRock
New York
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$188K |
| 2 |
Renaissance Technologies
New York
|
-$141K |
| 3 |
Two Sigma Investments
New York
|
-$104K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$87K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$27K |
PSTV Hedge Fund Activity: Q1 2022 in Review
14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2022, worth a combined $3.26M — up 61% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PSTV and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $1.55M. The largest seller was Two Sigma Advisers, cutting an estimated $188K.
- 14 institutional investors held Plus Therapeutics (PSTV) as of Q1 2022, down from 15 in Q4 2021.
- Funds reported $3.26M of Plus Therapeutics stock for Q1 2022, up 61% quarter-over-quarter.
- 3 funds opened new Plus Therapeutics positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Plus Therapeutics buyer in Q1 2022 was Parkman Healthcare Partners, an estimated $1.55M added.
- The largest Plus Therapeutics seller in Q1 2022 was Two Sigma Advisers, an estimated $188K sold.
Based on aggregated 13F filings for Q1 2022.